US Patent 5,602,176: Rivastigmine Claims, Expiration, Orange Book Status, and Patent Landscape

US Patent 5,602,176 covers the S-enantiomer of N-ethyl-3-(1-dimethylaminoethyl)-N-methylphenylcarbamate, now known as rivastigmine, including its hydrogen tartrate salt, pharmaceutical compositions, specified neurological uses, and systemic transdermal administration. The patent issued on February 11, 1997, and its enforceable US term expired in February 2014 under the pre-URAA patent-term rules applicable to the application. It no longer blocks generic rivastigmine capsules, oral solutions, or transdermal systems.

The patent was foundational for Exelon, marketed by Novartis for Alzheimer’s disease and Parkinson’s disease dementia. Its composition-of-matter protection was stronger than its later method, formulation, and delivery claims because the core S-enantiomer claim covered the active pharmaceutical ingredient across formulations and indications.

What drug does US Patent 5,602,176 protect?

US Patent 5,602,176 protects rivastigmine, specifically the S-enantiomer of the phenylcarbamate compound identified in the claims.

Patent element	Covered subject matter
Active ingredient	Rivastigmine, the S-enantiomer
Chemical form	Free base or acid-addition salt
Expressly claimed salt	Hydrogen tartrate, commonly called rivastigmine tartrate
Product protection	Pharmaceutical compositions containing rivastigmine
Medical uses	Dementia and specified neurological disorders
Delivery route	Systemic transdermal administration
Transdermal product	Rivastigmine-containing patch
Patent holder lineage	Sandoz-originated rights associated with the Novartis pharmaceutical business

Rivastigmine is an acetylcholinesterase inhibitor. The marketed oral product is rivastigmine tartrate. The marketed patch uses rivastigmine delivered through the skin in a transdermal therapeutic system.

The patent does not claim every acetylcholinesterase inhibitor. It claims a single stereochemically defined compound and products and uses that depend on it.

What is the legal scope of claim 1?

Claim 1 is the principal composition-of-matter claim. It covers:

The S-enantiomer of the specified phenylcarbamate;
The compound being substantially free of the R-isomer; and
The compound in either free-base form or acid-addition form.

The phrase “substantially free” is important. The claim is not limited to an analytically absolute 100% enantiopure material. It requires a degree of stereochemical enrichment sufficient to distinguish the claimed S-isomer from the racemic compound or an S/R mixture. The patent specification and prosecution history would be relevant to determining the precise impurity threshold in an infringement dispute.

Claim 1 is broad across salt forms. A generic manufacturer could not avoid the claim merely by selecting a different pharmaceutically acceptable acid salt during the patent term. The claim also reaches the free base, even though the commercial oral product was generally supplied as the hydrogen tartrate salt.

Why the S-enantiomer limitation mattered

The claim excludes the R-isomer as such. It also distinguishes rivastigmine from the racemate. A product containing a materially significant amount of the R-isomer could create a claim-construction and infringement issue, but intentional racemic substitution would not necessarily avoid all other patents or regulatory requirements.

The commercial value of the claim arose from its composition-of-matter character. Unlike a narrow formulation or method claim, it could cover the same active molecule regardless of whether the product was supplied as a capsule, oral solution, patch, or another pharmaceutical dosage form.

What does claim 2 cover?

Claim 2 covers the hydrogen tartrate salt of rivastigmine.

This claim is narrower than claim 1 because it is limited to one acid-addition salt. Its commercial relevance was high because rivastigmine hydrogen tartrate was the principal pharmaceutical form used in Exelon oral products. During the patent term, a product containing this salt could infringe both claim 1 and claim 2.

Claim 2 did not provide meaningful post-expiration protection after the expiration of claim 1. Once the composition-of-matter claim expired, the hydrogen tartrate salt could be developed by generic manufacturers unless another unexpired patent covered the particular product, process, or formulation.

What do claims 3 through 6 cover?

Claims 3 through 6 add product and treatment limitations.

Claim	Scope
3	Pharmaceutical composition containing rivastigmine with a carrier or diluent
4	Treatment of senile dementia
5	Treatment of Alzheimer’s disease
6	Treatment of Huntington’s chorea, tardive dyskinesias, hyperkinesia, mania, acute confusion disorders, Down’s syndrome, or Friedrich’s ataxia

Claim 3 is a composition claim, but it depends on claim 1. It therefore requires rivastigmine in free-base or acid-addition-salt form and a pharmaceutical carrier or diluent.

Claims 4 through 6 are method-of-treatment claims. They require:

The claimed disease or disorder;
Administration to a subject in need of treatment; and
A therapeutically effective amount of rivastigmine.

These claims are narrower than claim 1 because they require the specified clinical use. They would not have protected every commercial use of rivastigmine. Their practical enforcement value also depended on the ability to establish direct infringement by a relevant actor, induced infringement based on product labeling, or contributory infringement under the facts of a particular case.

The Alzheimer’s disease claim was commercially important because it aligned with the primary indication for Exelon. The list in claim 6 is broader diagnostically but less important commercially because several listed conditions were not the principal approved indications for Exelon.

What do claims 7 through 12 cover?

Claims 7 through 12 address transdermal delivery.

Claim	Scope
7	Method of systemic transdermal administration
8	Systemic transdermal composition containing rivastigmine
9	Systemic transdermal composition containing rivastigmine hydrogen tartrate
10	Claim 8 composition using rivastigmine free base
11	Claim 8 composition using a transdermal patch
12	Claim 7 method using rivastigmine free base

The transdermal claims do not claim every patch containing any drug. They require rivastigmine and systemic delivery through the skin.

Claim 7 is a method claim directed to the route of administration. Claims 8 through 11 are product or composition claims. Claim 11 narrows the carrier to a transdermal patch. Claim 9 is limited to the hydrogen tartrate salt, while claim 10 is limited to the free base.

This distinction matters because later Exelon patch patents focused on patch architecture, adhesive layers, drug reservoirs, release control, skin permeation, and dose delivery. Those patents could provide separate protection after the basic rivastigmine patent expired.

When did US Patent 5,602,176 expire?

US Patent 5,602,176 expired in February 2014, based on the statutory term applicable to the underlying pre-June 8, 1995 application and the February 11, 1997 issue date. No current enforcement position should be based on this patent.

Event	Date or period
Earliest priority period	Early 1990s
US filing framework	Pre-URAA application
Patent issued	February 11, 1997
Nominal US expiration	February 2014
Current status	Expired
Current composition-of-matter barrier	None from US 5,602,176

The exact patent-term calculation should be distinguished from FDA regulatory exclusivity. Patent expiration and FDA exclusivity are separate rights. Any Hatch-Waxman exclusivity associated with the original New Drug Application would have expired well before the current generic market.

What was the Orange Book status of US 5,602,176?

US 5,602,176 was historically associated with the Exelon NDA and the rivastigmine active ingredient. Its practical Orange Book significance was tied to the oral rivastigmine products and related regulatory filings.

The patent is no longer an effective Orange Book barrier because it has expired. Current generic applicants do not face a live patent term under this patent and do not need to wait for its expiration.

For an abbreviated new drug application, the historical patent certifications would have included a Paragraph IV certification if the applicant asserted that the listed patent was invalid, unenforceable, or would not be infringed. Once the patent expired, the practical certification issue became moot for new approvals.

Which companies challenged rivastigmine exclusivity?

Generic competition developed after the expiration of the core rivastigmine patent and related regulatory exclusivities. Generic manufacturers have marketed or obtained approvals for rivastigmine capsules, oral solutions, and transdermal systems.

The principal competitive groups include:

Novartis, through Exelon;
Sandoz-related generic operations;
Teva and associated generic applicants;
Mylan and later Viatris;
Dr. Reddy’s Laboratories;
Wockhardt;
Impax and other ANDA sponsors in the patch market.

The most relevant challenges to the commercial franchise concerned the Exelon patch rather than the expired composition claim in US 5,602,176. Patch applicants had to assess additional transdermal-system patents and potential Paragraph IV litigation involving later-issued patents.

What later patents protected the Exelon patch?

The Exelon patch franchise relied on later transdermal patents in addition to US 5,602,176. A frequently cited patent in the patch landscape is US Patent 6,335,031, directed to a transdermal therapeutic system containing rivastigmine.

Patent	General subject matter	Commercial relevance
US 5,602,176	Rivastigmine S-enantiomer, salts, uses, transdermal administration	Core active ingredient and early transdermal coverage
US 6,335,031	Rivastigmine transdermal therapeutic system	Patch formulation and delivery protection
Later patch patents	Adhesives, layers, release, dose delivery, and patch construction	Potential post-2014 barriers to patch ANDAs

The later patch patents were more technically specific than claim 1 of US 5,602,176. A generic patch could avoid one formulation patent while still encountering another if its adhesive matrix, drug loading, backing layer, release profile, or manufacturing process fell within the later claims.

The commercial patent analysis therefore requires a claim-by-claim review of the entire patch estate. The expiration of US 5,602,176 did not automatically eliminate every patent risk for a transdermal product.

Did US 5,602,176 create biosimilar risk?

No. Rivastigmine is a small-molecule drug, not a biologic. The relevant approval pathway is an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not the biosimilar pathway under section 351(k) of the Public Health Service Act.

The principal regulatory risks were:

Bioequivalence for capsules and oral solution;
Dose proportionality and delivery performance;
Adhesion and drug-release performance for patches;
Labeling differences;
Device and combination-product requirements for transdermal systems.

A biosimilar analysis is not applicable to Exelon or rivastigmine.

How strong was the patent estate?

The estate was strong during the protected period because US 5,602,176 combined a composition-of-matter claim with salt, composition, treatment, and transdermal claims. Its strongest feature was claim 1.

Estate component	Relative strength during term	Current position
S-enantiomer composition claim	Very high	Expired
Hydrogen tartrate salt claim	High	Expired
Oral pharmaceutical composition	Moderate to high	Expired
Alzheimer’s treatment claim	Moderate	Expired
Broad neurological-use claims	Moderate	Expired
Transdermal administration claim	Moderate	Expired
Patch-specific later patents	Potentially high for defined systems	Must be assessed individually

The weaknesses were structural. Claims 4 through 7 required proof of a specific medical use or route of administration. Claims 8 through 11 depended on additional composition limitations. Later generic litigation could therefore focus on whether the accused product contained the claimed salt, patch, carrier, or delivery configuration.

What generic launch scenarios existed?

Oral rivastigmine

Generic oral products could launch after the expiration of the core patent and any applicable regulatory exclusivity. The primary products were capsules and oral solution containing rivastigmine tartrate or an equivalent approved form.

Rivastigmine patches

Patch launch timing depended on the later transdermal patent estate. A generic applicant could pursue:

Paragraph III certification with launch after patent expiry;
Paragraph IV certification alleging invalidity, unenforceability, or non-infringement;
A design-around patch avoiding specific adhesive or delivery claims;
A settlement allowing a licensed or agreed launch date.

Patch litigation risk was higher than capsule litigation risk because the product incorporated additional delivery technology.

Were there licensing or settlement agreements tied to US 5,602,176?

No publicly established current license is required to commercialize ordinary generic rivastigmine after expiration of US 5,602,176. The patent’s expiration removed the need for a license under its claims.

Historical settlements involving Exelon patch ANDA applicants, where applicable, would have related primarily to later patch patents and commercial launch timing rather than to a continuing license under the expired ’176 patent. Settlement terms can include licensed entry dates, covenants not to sue, or agreements concerning specific patch designs, but those arrangements do not revive an expired composition patent.

What is the current commercial exposure?

The patent no longer creates direct revenue protection for Novartis. Its economic impact was concentrated in the period before generic entry.

Product	Patent exposure from US 5,602,176	Current competitive position
Exelon capsules	Core ingredient claim historically significant	Generic competition
Exelon oral solution	Core ingredient claim historically significant	Generic competition
Exelon patch	Early transdermal claim historically relevant	Later patch patents may matter
Rivastigmine generic API	No current barrier from ’176	Open small-molecule market
Rivastigmine transdermal systems	No current barrier from ’176	Product-specific patent review required

Revenue exposure is therefore linked to brand retention, physician preference, patch adherence, reimbursement, and later formulation patents rather than to US 5,602,176.

Key Takeaways

US Patent 5,602,176 covers rivastigmine, the S-enantiomer of the claimed phenylcarbamate.
Claim 1 is the central composition-of-matter claim and covers the free base and acid-addition salts.
Claim 2 specifically covers rivastigmine hydrogen tartrate.
Claims 3 through 6 cover pharmaceutical compositions and specified neurological treatments.
Claims 7 through 12 cover systemic transdermal administration, transdermal compositions, and patches.
The patent issued on February 11, 1997, and expired in February 2014.
It is no longer an effective Orange Book or Paragraph IV barrier.
Rivastigmine is a small molecule, so biosimilar law does not apply.
The remaining historical patent risk for Exelon patches came from later transdermal-system patents, not from the expired ’176 patent.
Generic capsule and oral-solution entry is no longer constrained by this patent.
Patch commercialization requires a separate review of later formulation, adhesive, delivery, and device claims.

FAQs

Is US 5,602,176 a patent on Exelon?

It is a foundational patent for Exelon because it covers rivastigmine and its hydrogen tartrate salt. It does not claim the Exelon trademark or every later patch technology.

Does US 5,602,176 cover rivastigmine patches?

Yes. Claims 7 through 12 cover systemic transdermal administration and transdermal compositions containing rivastigmine. Later patents may separately cover specific patch designs.

Can a company make generic rivastigmine tartrate today?

Yes, subject to FDA approval and compliance with any other unexpired patents applicable to the proposed product. US 5,602,176 itself expired in February 2014.

Does changing the rivastigmine salt avoid US 5,602,176?

No, not during the patent term. Claim 1 covers rivastigmine in free-base or acid-addition form, while claim 2 specifically covers the hydrogen tartrate salt.

Are rivastigmine products subject to biosimilar approval?

No. Rivastigmine is a small molecule and is approved through the generic-drug framework, principally the ANDA pathway.

References

United States Patent and Trademark Office. (1997). United States Patent No. 5,602,176: Enantiomer of N-ethyl-3-(1-dimethylaminoethyl)-N-methylphenylcarbamate and its use.
United States Patent and Trademark Office. (n.d.). Patent Term Calculator and patent term provisions.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations [Orange Book].
U.S. Food and Drug Administration. (n.d.). Exelon (rivastigmine tartrate) prescribing information.
United States Patent and Trademark Office. (1997). United States Patent No. 6,335,031: Transdermal therapeutic system containing rivastigmine.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	37 06 914.4	Mar 04, 1987

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	394190	⤷ Start Trial
Austria	A55188	⤷ Start Trial
Australia	1255488	⤷ Start Trial
Australia	618949	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,602,176

Summary for Patent: 5,602,176